Oramed Pharmaceuticals Inc.
ORMP Healthcare Biotechnology
In the quarter to June 2026, revenue grew 193.3%, EPS grew 493.8% and free cash flow grew 94.3%, each against the same quarter a year earlier.
Follow ORMP
Oramed Pharmaceuticals Inc. (ORMP) EV/Sales
As of 16 October 2026, Oramed Pharmaceuticals Inc. (ORMP) trades at a EV/Sales of 29.0×. Over the past ten years it has ranged from −39.2× (November 2023) to 419× (December 2021); the current reading is higher than 68% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −2.0× | — |
| FY2023 | −23.4× | — |
| FY2022 | 121× | (45.53%) |
| FY2022 | 223× | (46.90%) |
| FY2021 | 419× | 105.95% |
| FY2021 | 204× | 1,637.53% |
| FY2020 | 11.7× | 32.42% |
| FY2019 | 8.8× | (49.84%) |
| FY2018 | 17.6× | (54.39%) |
| FY2017 | 38.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | −10.5× | — |
| Jun 2023 | −2.3× | — |
| Mar 2023 | −24.6× | — |
| Dec 2022 | 121× | 16.10% |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −4.0× |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.1× |
| WHWK Whitehawk Therapeutics, Inc. compare | 1.9× |
| DTIL Precision BioSciences, Inc. compare | 1.9× |
| CHRS Coherus Oncology, Inc. compare | 5.1× |
| ACOG Alpha Cognition Inc. compare | 9.0× |
| ORMP Oramed Pharmaceuticals Inc. | 29.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)